Aragen Announces Expansion of Discovery Research Agreement with Boehringer Ingelheim
29.6.2021 09:30:00 EEST | Business Wire | Press release
Aragen Life Sciences (formerly GVK BIO), a leading Contract Research and Development Organization, headquartered out of Hyderabad, India, announces an expansion of their discovery research agreement with Boehringer Ingelheim, with the goal of accelerating the discovery pipeline of Boehringer Ingelheim.
This preferred partnership allows Boehringer Ingelheim, a leading research driven pharmaceutical company, to incorporate several design elements, synthesize, profile, and then characterize a wide range of chemotypes against key targets of interest in swift optimization cycles. The partnership also allows for the integrated up-scaling of compounds for larger pre-clinical studies. Biology screening of appropriate chemical moieties to drive decision making with speed and accuracy is also included in the partnership. Aragen will dedicate a sizeable portion of its campus in Hyderabad to support this alliance.
"We at Aragen believe that ‘In Every Molecule is the Possibility for Better Health’, and are excited about the opportunity to expand our partnership with Boehringer Ingelheim, a global leader in the discovery and development of novel medicines. It has been our privilege to collaborate with the scientists at Boehringer Ingelheim, and we thank them for their trust and confidence in the Aragen team. Together, we look forward to advancing Boehringer Ingelheim’s innovative approaches into successful clinical outcomes that can have the potential to ultimately benefit patients,” said Manni Kantipudi, CEO at Aragen.
About Aragen
Aragen Life Sciences Pvt Ltd (“Aragen”) is a global leader in providing discovery, development and manufacturing solutions for life sciences firms. With a team of over 3100 professionals, and through a network of sites around the world, we offer a seamless, integrated platform to advance customer programs from discovery through commercialization for both small molecules and biologics. Established in 2001, Aragen now serves over 450 customers worldwide across multiple modalities and therapeutic areas. For more information, visit www.aragen.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005162/en/
Contact information
Aragen Life Sciences: Sarat Patanaik, +91 95732 80064, sarat.patanaik@aragen.com
MediaMedic Communications Pvt.Ltd.: Bhavna Pathak, +918830654608, info@mediamedichealth.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku Accelerates Next-generation Semiconductor Metrology Development Leveraging World-Class Research Infrastructure12.5.2026 17:00:00 EEST | Press release
Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; “Rigaku”), announced the expansion of its development of metrology technologies for next-generation semiconductors, leveraging global research environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512888328/en/ Signing ceremony with imec held on April 9 As part of this initiative, Rigaku is working with imec, a world-leading semiconductor research and innovation hub headquartered in Belgium, under a three-year development program. Through this effort, Rigaku will advance its core X-ray technologies, including 3D device metrology, high-sensitivity detection of ultrathin films and trace elements, and non-destructive inspection of microscopic defects. As semiconductor devices evolve toward advanced architectures such as Gate-All-Around (GAA) and
Aster Guardians Global Nursing Award Announces Top 10 Finalists for 202612.5.2026 16:54:00 EEST | Press release
On the occasion of International Nurses Day, Aster DM Healthcare has announced the Top 10 finalists for the fifth edition of the Aster Guardians Global Nursing Award 2026, selected from over 134,000 registrations across 214* countries and economies. One of the Top 10 finalists will be honoured with the grand title and a prize of USD 250,000. Aster has appointed Ernst & Young LLP as the 'Process Advisors' of the award. EY has defined a three-stage evaluation process to determine the finalists and the winner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512872373/en/ Aster Guardians Global Nursing Awards 2026 - Top 10 Finalists (Photo: AETOSWire) The top 10 finalists for 2026 includes: Dr. Agimol Pradeep (United Kingdom), Dr. Aidah Alkaissi (Sweden), Dinah Sevilla (The Kingdom of Saudi Arabia), Dr. Hammoda Abu-Odah (Hong Kong SAR, China), Hindumbi Kaurom Kakkada (India), Johana Patricia Galvan Barrios (Colombia), Josephin
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress12.5.2026 16:30:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that data from key programs in its Hematology and Oncology franchises will be presented at the European Hematology Association (EHA) 2026 Congress, to be held June 11 - 14, 2026, in Stockholm, Sweden. “The breadth of the data that will be showcased at the 2026 EHA Congress highlights the continued advancement of our Hematology and Oncology pipeline and our focus on delivering differentiated medicines for patients with cancer and hematologic diseases,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “These presentations include findings from the frontMIND study, which support the U.S. and EU regulatory applications for tafasitamab (Monjuvi®/Minjuvi®) in patients with first-line diffuse large B-cell lymphoma (DLBCL). Additionally, data presentations for INCA033989, which support our Phase 3 trials, demonstrate the steady advancement of this molecularly targeted therapy that has the potential to revolutionize
Lenovo Enables One-Week Deployment of Production-Ready Agentic AI to Transform Enterprise Workflows12.5.2026 16:00:00 EEST | Press release
Lenovo is enabling enterprises to deploy production-ready, agentic AI solutions in as little as one week1, eliminating the long development cycles that typically delay AI from reaching production, while maintaining enterprise-grade security, governance, and control. This is not theoretical, independent analysis from Signal65 confirms these results in real-world deployments. Lenovo’s Knowledge Super Agent reduced time spent on knowledge-related tasks by 30%, saving up to 120 hours per employee annually. In multiple deployments, organizations reached production up to 24× faster than with custom-built approaches, demonstrating how faster, secure deployment translates directly into faster business outcomes. These results reflect faster deployment and more efficient AI utilization, where each interaction delivers measurable business value. Delivered through the Lenovo AI Library as part of Lenovo Hybrid AI Advantage™, this approach allows organizations to move directly from pilot to operati
Nikkiso Signs Agreement With Maran Tankers Management to Provide Aftermarket Service Support12.5.2026 16:00:00 EEST | Press release
Nikkiso Clean Energy & Industrial Gases Group (Nikkiso CE&IG) has announced today that it has signed a long-term service agreement with oil tanker shipping firm Maran Tankers Management Inc. Under the five-year agreement, Nikkiso CE&IG will deliver comprehensive global aftermarket support for Maran Tankers’ high pressure pumps, including scheduled cold end valve repairs at defined intervals. To guarantee minimal turnaround time, Nikkiso CE&IG will maintain critical inventory across its Marine Hubs worldwide, enabling cold ends to be received by vessels within days rather than the industry’s average of months. Nikkiso CE&IG will also provide technical guidance to Maran Tankers and carry out extended overhauls during scheduled dry-docking periods. Sean Fanniff, President of Nikkiso CE&IG’s Cryogenic Services Business Unit, said: “With Marine Hubs across Southeast Asia, Europe, the Middle East, the US, and China, we can provide our clients with a coordinated global approach and seamless p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom